Loading organizations...
Handok is a comprehensive healthcare company developing and supplying a broad portfolio of pharmaceutical products and health solutions. The firm’s offerings span prescription and over-the-counter drugs, medical devices, in vitro diagnostics, and digital healthcare, emphasizing prevention, diagnosis, and disease management. Handok leverages established global standard systems and advanced pharmaceutical technologies, including proprietary drug delivery systems, to enhance product efficacy and expand its therapeutic reach.
The company was founded in 1954 as Union Drugs Company by Mr. Kim Shin-kwon, who recognized the need for sophisticated pharmaceutical capabilities in post-war Korea. His initial vision led to groundbreaking technical collaborations, notably with Germany’s Hoechst AG in 1957, enabling domestic production of advanced medicines. The firm evolved from Handok Pharmaceuticals, establishing itself as a leader before rebranding to Handok in 2013 to signify its strategic expansion into a total healthcare enterprise.
Handok serves a wide array of healthcare consumers and patients by providing solutions across various medical needs. The company’s long-term vision positions it as "The Health Innovator," striving to improve human health and the quality of life globally. Handok continues to expand its business domains beyond traditional treatment, focusing on integrated healthcare services that include diagnostic and management solutions for future growth.
Key people at Handok.
Handok was founded in 1954 by Mark Hanikeri (Founder).
Handok has 2 tracked investments across 2 companies. The latest tracked deal is $80.0M Series B in Adicet Bio, Inc in October 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 2, 2019 | Adicet Bio, Inc | $80.0M Series B | — | Consensus Business Group, DSC Investment, Johnson & Johnson Innovation, KB Investment, Novartis, OCI Enterprises, OrbiMed, Pontifax, Regeneron Pharmaceuticals, Samsung, SBI JI Innovation Fund |
| Feb 20, 2019 | BIOMx | $32.0M Series B | 8VC, Johnson & Johnson Innovation, Mirae Asset, OrbiMed, Yaron Breski, SBI JI Innovation Fund, ROB Woodman | Chong KUN Dang Pharmaceutical, Consensus Business Group, KB Investment, Eric DE LA Fortelle |
Key people at Handok.